Journal
ONCOTARGET
Volume 7, Issue 23, Pages 35257-35269Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9135
Keywords
hepatocellular carcinoma; miR-592; hypoxia inducible factor-1 alpha; glycolysis; WSB1
Categories
Funding
- National Natural Science Foundation of China [81503028, 21372259, 81372478]
- Natural Science Foundation of Guangdong Province [S2013010011957]
- China Postdoctoral Science Foundation [2014M552706]
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) cells rapidly switch their energy source from oxidative phosphorylation to glycolytic metabolism in order to efficiently proliferate. However, the molecular mechanisms responsible for this switch remain unclear. In this study, we found that miR-592 was frequently downregulated in human HCC tissues and cell lines, and its downregulation was closely correlated with aggressive clinicopathological features and poor prognosis of HCC patients. Overexpression of miR-592 inhibited aerobic glycolysis and proliferation in HCC cells in vitro. Conversely, knockdown of miR-592 promoted HCC growth in both subcutaneous injection and orthotopic liver tumor implantation models in vivo. Mechanistically, miR-592 downregulation in human HCCs was correlated with an upregulation of WD repeat and SOCS box containing 1 (WSB1). We further showed that miR-592 directly binds to the 3'-UTR of the WSB1 gene, thus disrupting hypoxia inducible factor-1 alpha (HIF-1 alpha) protein stabilization. In turn, overexpression of WSB1 in HCC cells rescued decreased HIF-1a expression, glucose uptake, and HCC growth induced by miR-592. Collectively, our clinical data and functional studies suggest that miR-592 is a new robust inhibitor of the Warburg effect and a promising therapeutic target for HCC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available